Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discipline keeps budgets on track amid temptations to overspend. Learn why steady habits matter and how to cultivate them for lasting budgeting success.
23,400 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A longtime investor reevaluates the urge to claim Social Security at 62, choosing to wait for bigger monthly checks a...
A sub-$1 pre-IPO company behind a headset-first work platform says 1.5m+ people spend their work week in headsets. It...
Zillow reports a strong start to 2026 with rising revenue and a bold pre-marketing push. The Zillow Preview program d...
Investors are watching Friday’s April payroll report for signs that businesses really starting hire signals a broader...
Discover how Hudson Pacific Properties is shaping its 2026 path after Q1 results. This guide breaks down earnings sig...
The Trade Desk faced a tougher path after missing Q1 revenue and guiding for a weaker Q2, triggering multiple downgra...
A biotech rally can be thrilling, but a large fund selling into the run-up often signals caution. This article unpack...
The S&P 500 surged to a new high driven by a small group of mega-cap tech giants, even as hundreds of other component...
Santa Clara County filed a landmark lawsuit against Meta, accusing the company of profiting from scam advertisements ...
Meta's internal AI model is circulating a long-range Bitcoin forecast for end-2026, highlighting supply constraints, ...
Disney reports a profitable quarter for its streaming arm, marking a profitability milestone that could spark upside ...